Publication at Faculty of Medicine in Hradec Králové |
2011
Abstract
Denosumab is a new drug designed for the treatment of osteoporosis. It is a fully human IgG2 monoclonal antibody which binds with high affinity and specificity to RANKL (receptor activator of nuclear factor NF-kappa-B-ligand).
Denosumab decreases bone resorption by inhibiting osteoclast formation, function and survival. Clinical trials have proven the effect of denosumab on bone mineral density and, especially, on fracture rate reduction.
The purpose of this review is to summarise the current knowledge on the effects of denosumab in the treatment of osteoporosis.